Old Web
English
Sign In
Acemap
>
authorDetail
>
Chirag Patel
Chirag Patel
Millennium Pharmaceuticals
Pharmacodynamics
Pharmacology
Medicine
Tolerability
Gene isoform
3
Papers
15
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
First-in-human, phase I, dose-escalation study of selective PI3K{alpha} isoform inhibitor MLN1117 in patients (pts) with advanced solid malignancies.
2015
Journal of Clinical Oncology
Dejan Juric
Johann S. de Bono
Patricia LoRusso
John Nemunaitis
Elisabeth I. Heath
Eunice L. Kwak
Teresa Macarulla
Elena Geuna
Maria Jose de Miguel Luken
Chirag Patel
Keisuke Kuida
Serap Sankoh
Fabian Zohren
Yaping Shou
Josep Tabernero
Show All
Source
Cite
Save
Citations (8)
Abstract A216: Combination schedule optimization through preclinical PK-efficacy modeling of an investigational novel-novel combination: A case study of MLN0128 an mTORC1/2 inhibitor with MLN1117 a PI3Kα isoform selective inhibitor.
2013
Molecular Cancer Therapeutics
Christopher J. Zopf
Mayank Patel
Ekta Kadakia
Robyn Fabry
Arijit Chakravarty
Swapan Chowdhury
Jing-Tao Wu
Wen Chyi Shyu
Mark Manfredi
Fabian Zohren
Chirag Patel
Keisuke Kuida
Natasha Iartchouk
Rachael L. Brake
Jerome Mettetal
Show All
Source
Cite
Save
Citations (0)
MLN0128 (INK128), an Investigational Oral Dual TORC1/2 Inhibitor, in Patients (pts) with Relapsed or Refractory Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), or Waldenstrom Macroglobulinemia (WM): Preliminary Results From a Phase 1 Dose-Escalation Study
2012
Blood
Irene M. Ghobrial
David Siegel
Ravi Vij
Jeffrey L. Wolf
Jesus G. Berdeja
Jeffrey Matous
Peter Lipman
Chirag Patel
Trinh Le
Christian Rommel
Gregory Berk
Show All
Source
Cite
Save
Citations (7)
1